Seres Therapeutics, Inc. (MCRB) Stock Price & Analysis
Seres Therapeutics, Inc. (MCRB) is trading at USD 2.1, down 1.41% today, as of October 23, 2026 at 15:04 UTC (US market open; quotes may be delayed), according to Nexqual market data.
MCRB last closed at USD 2.13; today's session has ranged USD 2.05–2.17 on volume of 30,226 shares. Market capitalization is $21.09M, with a 52-week range of USD 2.02–29.98 (NMS). Source: Nexqual, retrieved October 23, 2026 at 15:07 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MCRB.md
Key facts (MCRB)
- Last four reported quarters (through Jun 30, 2026): revenue $1.9M, net income -$22.5M (-1192.9% margin), free cash flow -$51.3M (SEC filings).
- Insider open-market sales, last ~7 months: 8 Form 4 filings, $6K; 1 not under a Rule 10b5-1 plan ($0K); 6 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 17 (range 12–22).
- Total return with dividends: 1Y -88.2% vs S&P 500 +14.8%; 5Y -98.3% vs S&P 500 +77.5%.
- Next earnings: 2026-11-04, EPS estimate USD -1.01, revenue estimate $6.3M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MCRB)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $145M | $7.1M | $0K | $0K | $789K | $1.9M |
| Operating income | -$64.5M | -$180M | -$195M | -$121M | -$94.0M | -$84.0M |
| Net income | -$65.6M | -$250M | -$114M | $136K | $5.7M | -$22.5M |
| EPS (diluted) | -$14.40 | -$46.20 | -$17.77 | $0.00 | $0.64 | — |
| Free cash flow | -$2.9M | -$239M | -$125M | -$149M | $865K | -$51.3M |
| Operating margin | -44.5% | -2524.0% | — | — | -11910.1% | -4462.8% |
| Net margin | -45.2% | -3509.5% | — | — | 721.9% | -1192.9% |
| Revenue growth | +336.3% | -95.1% | -100.0% | — | — | — |
| Cash + short-term investments | $291M | $181M | $128M | — | — | — |
| Total debt | $24.1M | $50.0M | $110M | $0K | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MCRB)
P/S 11.2x · P/B 0.6x · FCF yield -243.17% · Earnings yield -106.49%
P/E at fiscal year-ends: Dec 2025 23.2x, Dec 2024 949.5x.
Insider sales (SEC Form 4, open-market, last ~7 months) (MCRB)
7 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Brady Kelly | See Remarks | 64 | $0K | 0.7% | Yes (adopted November 26, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-08-17 | Shaff Eric D. | Director | 263 | $1K | 2.1% | Yes (adopted March 2, 2023) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-17 | Henn Matthew R | See Remarks | 81 | $0K | 1% | Yes (adopted April 13, 2023) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-17 | Desrosier Thomas | See Remarks | 82 | $0K | 1% | Yes (adopted March 2, 2023) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-18 | Shaff Eric D. | Director | 259 | $2K | 2.1% | Yes (adopted March 2, 2023) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-18 | Desrosier Thomas | See Remarks | 79 | $1K | 1% | Yes (adopted March 2, 2023) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-18 | Brady Kelly | See Remarks | 59 | $0K | 0.7% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-18 | Henn Matthew R | See Remarks | 77 | $1K | 1% | Yes (adopted April 13, 2023) | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (MCRB)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 17 (low 12, high 22).
Total return (dividends reinvested) (MCRB)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -88.2% | -98.3% |
| S&P 500 (SPY) | +14.8% | +77.5% |
| Per year | -88.2% | -55.6% |
| Volatility (annualized) | 96.4% | 93.0% |
| Max drawdown | -92.7% (Nov 2025→Oct 2026) | -99.0% (Nov 2021→Oct 2026) |
MCRB company outlook (results filed Aug 5, 2026)
- “The restructured 10-year lease is expected to materially reduce the Company's ongoing annual facility-related cash costs and long-term lease obligations. In June, Seres entered into an amendment to its asset purchase agreement with Nestlé”
- “Health Science (Nestlé) under which Nestlé will pay Seres an aggregate $25 million (the Milestone Termination Payment), in two equal installments of $12.5 million on July 1, 2026 (which was received) and $12.5 million which is expected to be received on October 1, 2026, to buy out potential future VOWST net sales-based milestones.”
- “Based on Seres' currently available cash resources, including the $12.5 million Milestone Termination Payment received from Nestlé on July 1, 2026, and the expected receipt of the remaining $12.5 million Milestone Termination Payment from Nestlé on October 1, 2026, and considering future operating plans, the Company expects to fund operations through the first quarter of 2027.”
- “(6) we may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company;”
Quoted word-for-word from the SEC 8-K results press release.
MCRB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-1.00 | $-2.37 | -57.6% | $6.3M | 2 |
| Next quarter (ends Dec 2026) | $-1.01 | $-2.33 | -56.4% | $6.4M | 2 |
| Current fiscal year (ends Dec 2026) | $-3.52 | $-9.19 | -61.8% | $13.8M | 2 |
| Next fiscal year (ends Dec 2027) | $-4.95 | $-10.28 | -51.9% | $273,500 | 2 |
MCRB options: expected move
Options price a move of about ±144.8% (±$3.23) by Jan 15, 2027, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±5.7% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Jan 15, 2027 | 84 | 294.5% | ±144.8% |
| Apr 16, 2027 | 175 | 207.3% | ±59.2% |
30-day implied volatility 96.7% vs 57.9% realized over the last 30 trading days. Put/call ratio (volume) 0.03. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 15:07 UTC)
| Price | USD 2.1 |
|---|---|
| Change | ▼ 1.41% (down) |
| Previous Close | USD 2.13 |
| Open | USD 2.13 |
| Day Range | USD 2.05 – 2.17 |
| 52-Week Range | USD 2.02 – 29.98 |
| Volume | 30,226 shares |
| Market Cap | $21.09M |
| Exchange | NMS |
Technical Analysis (MCRB)
Nexqual's technical model rates MCRB "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 15:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 9.8 (oversold) |
| vs SMA50 | Below (USD 3.88) |
| MACD | -0.5 (negative) |
Analyst Ratings (MCRB)
Wall Street analysts rate MCRB "Buy" based on 2 analysts, with a mean price target of USD 17 (range USD 12–22), per Nexqual as of October 23, 2026 at 15:07 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 17 |
| High Target | USD 22 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (MCRB)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -1.01 |
| Revenue Estimate | $6.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.07 vs est -2.19 ▲ beat |
| 2026-03-31 | USD -2.08 vs est -1.88 ▼ miss |
| 2025-12-31 | USD -1.76 vs est -1.6 ▼ miss |
| 2025-09-30 | USD 0.94 vs est 1.28 ▼ miss |
Source: Nexqual, October 23, 2026 at 15:07 UTC.
Financials & Fundamentals (MCRB)
| Total Revenue | $1.88M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -2101.36% |
| Profit Margin | +0.00% |
| ROE | -66.57% |
| Debt / Equity | 1.64 |
| Current Ratio | 2.11 |
| Total Cash | $15.59M |
| Total Debt | $56.64M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$51.30M (-2724.1% of revenue) |
Source: Nexqual, October 23, 2026 at 15:07 UTC.
Financial Health Score (MCRB)
Nexqual rates Seres Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 15:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $16M cash vs $57M debt |
| Cash Flow | Weak — FCF negative: -$51M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -67%, ROA -39.8% |
Ownership (MCRB)
| Insider Ownership | +11.49% |
|---|---|
| Institutional Ownership | +22.84% |
| Shares Outstanding | 10.04M |
| Float | 8.74M |
| Short % of Float | +4.05% |
Source: Nexqual, October 23, 2026 at 15:07 UTC.
Leadership (MCRB)
Seres Therapeutics, Inc. is led by Richard N. Kender B.S., Interim CEO & Executive Chair, per Nexqual as of October 23, 2026 at 15:07 UTC.
| Interim CEO & Executive Chair | Richard N. Kender B.S. |
|---|---|
| President & Chief Scientific Officer | Matthew R. Henn |
| Executive VP, CFO & Treasurer | Marella Thorell |
| Executive VP & COO | Kelly Brady M.S. |
| Executive VP & CTO | Chris McChalicher |
Major Backers & Investors (MCRB)
Notable institutional backers of Seres Therapeutics, Inc. include Flagship Pioneering LLC, Marshall Wace LLP, Vontobel Holding Limited, according to Nexqual as of October 23, 2026 at 15:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Flagship Pioneering LLC | 11.51% |
| Marshall Wace LLP | 1.71% |
| Vontobel Holding Limited | 1.14% |
| Fidelity | 0.63% |
| Susquehanna International Group, LLP | 0.58% |
| Lion Point Capital, LP | 0.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.34% |
| BlackRock | 1.11% |
| Geode Capital | 0.8% |
| State Street | 0.34% |
Source: Nexqual, October 23, 2026 at 15:07 UTC.
From Seres Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- We have built and deploy a reverse translational platform and knowledge base, which we call our MbTx Platform, for the discovery and development of live biotherapeutics, and maintain extensive proprietary know-how that may be used to support future research and development efforts.
- We have developed a field leading reverse translational biotherapeutics platform and knowledge base which we believe enables us to apply our capabilities to efficiently identify, manufacture and develop novel live biotherapeutics for serious human diseases.
- Our proprietary strain library of bacterial isolates from healthy donors and patients enables us to translate microbiome biomarker insights into defined consortia of bacteria.
- We believe that the combination of experience, proprietary data and proprietary know-how related to the microbiome, the functional properties of microbial species and strains, microbe-host interactions, the cultivation of microbial strains, and microbiome-specific functional screens and analytics provides us a competitive advantage in the design and development of live biotherapeutics.
Partnerships
- Following advancement of key startup activities for the SER-155 Phase 2 study in allo-HSCT, including the submission of a final protocol to the FDA in January 2026, study site evaluation and qualification with our CRO, and manufacturing of drug substance, we have paused additional investment in that program, preserving the optionality to efficiently restart the study, while continuing to seek funding for the Phase 2 study.
- Having finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allo-HSCT with the FDA and having advanced key study startup activities for this program, we will pause further investment while efforts to seek funding for the study remain ongoing.
Legal & Regulatory Risks (Item 1A, quoted)
- Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.
- Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
- Current and future legislation or regulation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may adversely affect the prices we may obtain.
- We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.52 | ▼ 0.1% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.45 | ▼ 1.6% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 13.83 | ▼ 2.21% |
| PRAX | Praxis Precision Medicines, Inc | USD 254.03 | ▼ 1.89% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.83 | ▼ 2.46% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.48 | ▼ 6.79% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 15:07 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt